Depression

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

Case reports have shown a potential association with adverse psychological effects.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

The CBT-based intervention, compared with routine pregnancy care, demonstrated reductions of 81% and 74% for depression and anxiety, respectively.

The dynamic reconfigurations in individuals taking antidepressant were higher than in non-users and controls, with no significant differences between those with MDD or an anxiety disorder.

One significant difference was an increased rate of bupropion prescriptions for transgender females.

Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.

The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.

Investigators determined the effectiveness of behavioral activation psychotherapy versus antidepressant medication management for inpatients with heart failure and depression.

As the body of data has grown, clinicians’ propensity to use selective serotonin reuptake inhibitors off-label has increased

Gepirone does not induce sexual dysfunction, a common limitation associated with SSRIs.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

Pharmacists are accessible and trusted health care professionals who have an important role in supporting people living with mental illness.

Modern society has put individuals at an increased risk of dopamine overload, causing an increase in mental health disorders.

Person-centered care focuses on tailoring treatment plans, providing medication support, and ensuring access to resources that meet their unique needs.

Latinx teens suffering with mental health issues are at risk of developing cardiovascular conditions in their future.

Mental health treatment may be necessary when SAEs occur.

Adolescents with mental health conditions must be monitored as they are at a higher demand for the need of mental health care.

Patients under the care of psychiatric facilities, particularly those taking antipsychotic and antidepressant medications, face the risk of prolonged QTc intervals.

Individuals treated with esketamine were more likely to reach remission and remain relapse-free at 8 weeks of treatment.

Use of antidepressants and other classes of prescription drugs can increase the risk of driving impairment compared to nonuse, so clinicians and pharmacists should review these risks with older adults.

The use of psilocybin, repeated at a low dose, could offer a new form of treatment for individuals with differing forms of mental disorders.

Ketamine topical cream may alleviate symptoms of PTSD without causing the adverse effects and abuse potential often associated with other forms of ketamine administration.